"We believe that there are several drivers for increased application and acceptance of Blow-Fill-Seal technology."

Alan Petro

CEO, NEW VISION PHARMACEUTICALS

June 16, 2021

Can you provide an overview of New Vision Pharmaceuticals?

New Vision Pharmaceuticals is focused on providing exact dose Blow-Fill-Seal technology for a wide variety of formulations and products.  We provide confidence and quality to the Rx, OTC, diagnostic reagent, cosmetic and dietary supplement markets. We help clients make their product through reformulation, more economical production methods, better packaging and improved customer presentation.

What are the underlying trends diving the adoption of Blow-Fill-Seal technology?

There are a number of reasons why Blow-Fill-Seal technology is being adopted more widely. Drugs are becoming more potent and doses are getting smaller. Therefore, the doses must be more precise. At the same time, the global population is getting older and drug packaging must become more patient-centric and easier to use. Especially with seniors, the packaging must be easy to use to allow treatment in the home. Blow-Fill-Seal packaging is ideally suited to meet these needs. This need has been especially important as we have transitioned through a variety of lockdowns that limit access to the traditional points of medical care.

Blow-Fill-Seal technology is recognized by USP 1116 as an advanced aseptic process that allows for superior microbiological control, precise filling accuracy, exceptional process and product reliability, the capacity to apply inert cover gases and adapts to a wide variety of formulations.  It has concomitant advantages of being significantly lighter in weight than glass containers, unbreakable in transit and not subject to spoiling.  These factors result in lower shipping costs and fewer potential end-to-end quality concerns.  It has the additional benefit of being counterfeit resistant which enhances public confidence and overall safety.

While Blow-Fill-Seal technology has been long been established in Europe, its introduction in the US and Asia is accelerating. Even though the production equipment is costly to purchase and maintain, it provides excellent economy of scale through its high production rate, exquisite quality and low labor requirements.  It enables highly automated, precision manufacturing which delivers quality products in a very cost effective manner.

How does Blow-Fill-Seal boost adherence?

One of the unique aspects of Blow-Fill-Seal is the single use doses that in many cases are sterile. This enables us to reduce the issues of overdosing in pediatric cases. 

What are the most important areas of growth and investment for New Vision?

Today we are adding high volume Blow-Fill-Seal capacity to meet customer needs. As we speak, another machine is being prepared for shipment from Germany and will be fully operational later this year.  This will bring to six the number of BFS machines in house.  We anticipate making investments in the support systems, including enhancing track and trace to support evolving regulatory needs.

We are also focusing on developing an empowered and highly flexible organization that can bring client ideas to fruition more quickly.  This means that concepts can move rapidly into phase 2 production and later easily transition to phase 3 and ultimately commercial manufacturing.   We believe that there are several drivers for increased application and acceptance of Blow-Fill-Seal technology.   These trends suggest that New Vision Pharmaceuticals is well positioned for market growth.

What are the primary goals of the company moving forward?

Our primary goals are to fully utilize the significant investment that we have made over the last several years in the facility and staff.  We have an excellent team who have demonstrated the ability to give clients the quality and schedule reliability they need to deliver innovative products.  In the coming years we want to do the same, but with quicker project schedules and the ability to assist if and when the next public health issue presents itself.  Through our capabilities, we can quickly bring generics to market, reduce our country’s dependence on offshore drug manufacturing and deliver products with enhanced anti-counterfeiting features.

INTERVIEWS MORE INTERVIEWS

"At present, much of our work in KSA focuses on early-stage exploration and resource evaluation simply because the industry has not yet reached the more advanced stages."
"I anticipate greater support for North American supply chains. For example, Ontario is investing over C$40 billion in midstream and downstream EV development."
"In the current gold price environment, when operators have the capital to spend on putting new mines into production and expanding existing mines, there is tremendous organic growth."
"If you are able to build a great relationship with a company while expediting and providing quality work, it will set you apart as an engineering firm to be trusted in the industry."

RECENT PUBLICATIONS

Latin America Petrochemicals and Chemicals 2024 - Digital Interactive

The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.

MORE PREVIOUSLY PUBLISHED

MACIG

"With the increasing mining activity in Africa, it is fundamental to ensure that these minerals are produced more sustainably and timely manner."

SUBSCRIBE TO OUR NEWSLETTER